References
- Steffens NA, Zimmermann ES, Nichelle SM, Brucker N. Meropenem use and therapeutic drug monitoring in clinical practice: a literature review. J Clin Pharm Ther. 2021;46(3):610–621.
- Mariani M, Scaglione M, Russo C, Rainelli A, Mesini A, Saffioti C, et al. A Real-Life Study of Prolonged Meropenem Infusion in Neonates and Children Admitted to Intensive Care Units: Are Three Hours Long Enough? J Clin Med. 2025;14(5):1488.
- Agencija za lekove i medicinska sredstva Republike Srbije. Meropenem-Sažetak karakteristika leka. Available at:
https://www.alims.gov.rs/doc_file/lekovi/smpc/515-01-04339-17-001.pdf . - Garnica-Velandia S, Aristizábal-Ruiz LA, Alvarez-Moreno CA. Real-World Use of Generic Meropenem: Results of an Observational Study. Antibiotics (Basel). 2021;10(1):62.
- Kollef MH, Torres A, Shorr AF, Martin-Loeches I, Micek ST. Nosocomial Infection. Crit Care Med. 2021;49(2):169–187.
- Venkateswaran P, Vasudevan S, David H, Shaktivel A, Shanmugam K, Neelakantan P, et al. Revisiting ESKAPE Pathogens: virulence, resistance, and combating strategies focusing on quorum sensing. Front Cell Infect Microbiol. 2023;13:1159798.
- Roberts JA, Lipman J. Pharmacokinetic issues for antibiotics in the critically ill patient. Crit. Care Med. 2009;37:840–851.
- Wang ZM, Chen XY, Bi J, Wang MY, Xu BP, Tang BH, et al. Reappraisal of the Optimal Dose of Meropenem in Critically Ill Infants and Children: a Developmental Pharmacokinetic-Pharmacodynamic Analysis. Antimicrob Agents Chemother. 2020;64(8):e00760–20.
- Roberts JA, Abdul-Aziz MH, Lipman J, Mouton JW, Vinks AA, Felton TW, et al; International Society of Anti-Infective Pharmacology and the Pharmacokinetics and Pharmacodynamics Study Group of the European Society of Clinical Microbiology and Infectious Diseases. Individualised antibiotic dosing for patients who are critically ill: challenges and potential solutions. Lancet Infect Dis. 2014;14(6):498–509.
- Roberts JA, Ulldemolins M, Roberts MS, McWhinney B, Ungerer J, Paterson DL, et al. Therapeutic drug monitoring of beta-lactams in critically ill patients: proof of concept. Int J Antimicrob Agents. 2010;36(4):332–9.
- Delattre IK, Taccone FS, Jacobs F, Hites M, Dugernier T, Spapen H, et al. Optimizing β-lactams treatment in critically-ill patients using pharmacokinetics/pharmacodynamics targets: are first conventional doses effective? Expert Rev Anti Infect Ther. 2017;15(7):677–688.
- Abdul-Aziz MH, Alffenaar JC, Bassetti M, Bracht H, Dimopoulos G, Marriott D, et al; Infection Section of European Society of Intensive Care Medicine (ESICM); Pharmacokinetic/pharmacodynamic and Critically Ill Patient Study Groups of European Society of Clinical Microbiology and Infectious Diseases (ESCMID); Infectious Diseases Group of International Association of Therapeutic Drug Monitoring and Clinical Toxicology (IATDMCT); Infections in the ICU and Sepsis Working Group of International Society of Antimicrobial Chemotherapy (ISAC). Antimicrobial therapeutic drug monitoring in critically ill adult patients: a Position Paper. Intensive Care Med. 2020;46(6):1127–1153.
- Roberts JA, Roberts MS, Semark A, Udy AA, Kirkpatrick CM, Paterson DL, et al. Antibiotic dosing in the 'at risk' critically ill patient: Linking pathophysiology with pharmacokinetics/pharmacodynamics in sepsis and trauma patients. BMC Anesthesiol. 2011;11:3.
- Luque S, Benítez-Cano A, Larrañaga L, Sorlí L, Navarrete ME, Campillo N, et al. Pharmacokinetics and Pharmacodynamics of Meropenem by Extended or Continuous Infusion in Low Body Weight Critically Ill Patients. Antibiotics (Basel). 2021;10(6):666.
- Kollef MH, Sherman G, Ward S, Fraser VJ. Inadequate antimicrobial treatment of infections: a risk factor for hospital mortality among critically ill patients. Chest. 1999;115(2):462–74.
- Rančić A, Folić M, Petrović N, Ilić Todorović V, Stanojević M, Milosavljević M, et al. Validation of novel high-performance liquid chromatography method for meropenem quantification in plasma. Acta Pol Pharm. 2024;81(1):71–82.
- European Committee on Antimicrobial Susceptibility Testing Data. Breakpoint tables for interpretation of MICs and zone diameters. Available at:
https://www.eucast.org/fi7leadmin/src/media/PDFs/EUCAST_files/Breakpoint_tables/v_15.0_Breakpoint_Tables.pdf . - Chiriac U, Richter D, Frey OR, Röhr AC, Helbig S, Hagel S, et al. Software- and TDM-Guided Dosing of Meropenem Promises High Rates of Target Attainment in Critically Ill Patients. Antibiotics (Basel). 2023;12(7):1112.
- Scharf C, Paal M, Schroeder I, Vogeser M, Draenert R, Irlbeck M, et al. Therapeutic Drug Monitoring of Meropenem and Piperacillin in Critical Illness-Experience and Recommendations from One Year in Routine Clinical Practice. Antibiotics (Basel). 2020;9(3):131.
- Ayukekbong JA, Ntemgwa M, Atabe AN. The threat of antimicrobial resistance in developing countries: causes and control strategies. Antimicrob Resist Infect Control. 2017;6:47.
- Guilhaumou R, Benaboud S, Bennis Y, Dahyot-Fizelier C, Dailly E, Gandia P, et al. Optimization of the treatment with beta-lactam antibiotics in critically ill patients-guidelines from the French Society of Pharmacology and Therapeutics (Société Française de Pharmacologie et Thérapeutique-SFPT) and the French Society of Anaesthesia and Intensive Care Medicine (Société Française d'Anesthésie et Réanimation-SFAR). Crit Care. 2019; 23(1):104.
- Imani S, Buscher H, Day R, Gentili S, Jones GRD, Marriott D, et al. An evaluation of risk factors to predict target concentration non-attainment in critically ill patients prior to empiric β-lactam therapy. Eur J Clin Microbiol Infect Dis. 2018;37(11):2171–2175.
- Muller AE, Huttner B, Huttner A. Therapeutic Drug Monitoring of Beta-Lactams and Other Antibiotics in the Intensive Care Unit: Which Agents, Which Patients and Which Infections? Drugs. 2018;78(4):439–451.
- de With K, Allerberger F, Amann S, Apfalter P, Brodt HR, Eckmanns T, et al. Strategies to enhance rational use of antibiotics in hospital: a guideline by the German Society for Infectious Diseases. Infection. 2016;44(3): 395–439.
- Rančić A. Methods for Determination of Meropenem Concentration in Biological Samples. Experimental and Applied Biomedical Research. 2022. doi: 10.2478/sjecr-2022-0005.
- Angelini J, Giuliano S, Flammini S, Pagotto A, Lo Re F, Tascini C, et al. Meropenem PK/PD Variability and Renal Function: “We Go Together”. Pharmaceutics. 2023;15(9):2238.
- Folic MM, Jankovic SM. Factors affecting outcome in hospitalized patients treated according to recommendations from clinical pharmacologists. Int J Clin Pharmacol Ther. 2023;61(8):339–345.
- Borgmann S, Wolz C, Gröbner S, Autenrieth IB, Heeg P, Goerke C, et al. Metallo-beta-lactamase expressing multi-resistant Acinetobacter baumannii transmitted in the operation area. J Hosp Infect. 2004;57(4):308–15.
- Maragakis LL, Perl TM. Acinetobacter baumannii: epidemiology, antimicrobial resistance, and treatment options. Clin Infect Dis. 2008;46(8):1254–63.
- Feng Y, Chen X, Sun Y, Guo T, Wu F, Jin F, et al. Synergistic effect and mechanism of meropenem with ciprofloxacin against carbapenem-resistant Acinetobacter baumannii. Front Pharmacol. 2025;16:1534155.
- Choi SJ, Kim ES. Optimizing Treatment for Carbapenem-Resistant Acinetobacter baumannii Complex Infections: A Review of Current Evidence. Infect Chemother. 2024;56(2):171–187.
- Paul M, Daikos GL, Durante-Mangoni E, Yahav D, Carmeli Y, Benattar YD, et al. Colistin alone versus colistin plus meropenem for treatment of severe infections caused by carbapenem-resistant Gram-negative bacteria: an open-label, randomised controlled trial. Lancet Infect Dis. 2018;18:391–400.
- Kaye KS, Marchaim D, Thamlikitkul V, Carmeli Y, Chiu CH, Daikos G, et al. Colistin Monotherapy versus Combination Therapy for Carbapenem-Resistant Organisms. NEJM Evid. 2023;2(1):10.1056/evidoa2200131.
- Farrington N, Dubey V, Johnson A, Horner I, Stevenson A, Unsworth J, et al. Molecular pharmacodynamics of meropenem for nosocomial pneumonia caused by Pseudomonas aeruginosa. mBio. 2024;15(2):e0316523.
- Avent ML, McCarthy KL, Sime FB, Naicker S, Heffernan AJ, Wallis SC, et al. Evaluating Mono- and Combination Therapy of Meropenem and Amikacin against Pseudomonas aeruginosa Bacteremia in the Hollow-Fiber Infection Model. Microbiol Spectr. 2022;10(3):e0052522.
- Taccone FS, Cotton F, Roisin S, Vincent JL, Jacobs F. Optimal meropenem concentrations to treat multidrug-resistant Pseudomonas aeruginosa septic shock. Antimicrob Agents Chemother. 2012;56(4):2129–31.